| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
 COVID-19 portal |
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic. [1] [2] [3] [4]
On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects. [5]
Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies.
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.
ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
iNCOVACC is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, American company Precision Virologics and the Washington University School of Medicine in St Louis, Missouri, United States.
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc. It is a peptide vaccine.
Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful, is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences.
Minhai COVID-19 vaccine, trademarked as KCONVAC, is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.
Turkovac is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.
GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.
mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.
COVAX-19 is the result of a collaboration between Vaxine and CinnaGen, a private company with operations in the Middle East. COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine. It is under clinical trial in collaboration with the Iranian company CinnaGen.
Skycovione is a COVID-19 vaccine candidate developed by SK Bioscience and the Institute for Protein Design of the University of Washington, It is South Korea's first homegrown Covid-19 vaccine and utilizes GSK's AS03 adjuvant technology.
AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co, a company from South Korea.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:
202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech. It is one of several candidates under development by Walvax.
ReCOV is a COVID-19 vaccine candidate developed by Jiangsu Rec-Biotechnology Co Ltd.
AKS-452 is a COVID-19 vaccine candidate developed by Akston Biosciences.
LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd.
Vaxart COVID-19 vaccine is a COVID-19 vaccine candidate developed by Vaxart.
Stemirna COVID-19 vaccine is a COVID-19 vaccine candidate developed by Stemirna Therapeutics.
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
